Oncology

New method examines the genetic background of tumors for more effective prostate cancer therapy.

Treatment shows promise in fighting lymphoma in early studies.

New analysis provides faster tests and lower costs for women with estrogen positive-receptor (ER-positive) breast cancer.

Recent advances and updates in oncology and cancer drug development.

Ibrutinib (Imbruvica) is the first FDA-approved chemotherapy-free treatment for patients with chronic lymphocytic leukemia (CLL).

Ibrutinib (Imbruvica) is the first chemotherapy-free treatment for first line CLL patients approved by the FDA.

Abraxane treats patients with advanced, squamous non-small cell lung cancer (NSCLC).

With recent therapeutic advances, the treatment landscape for metastatic castration-resistant prostate cancer is changing rapidly.

Durvalumab and tremelimumab was active in patients with or without tumor expression of PD-L1 in NSCLC.

Medication spending waste can be reduced with smaller vials of cancer drugs, study finds.

High cost infused cancer drugs are packaged containing quantities larger than needed to treat patients.

Adherence patterns and other risk factors predict increased utilization of acute care by outpatients with cancer pain.

Controversy swirls around the naming protocol for biosimilars among drug manufacturers and the FDA.

Men diagnosed with cancer under age 25 far less likely to have children and more likely to take infertility drugs.

Several chemotherapy agents have been investigated for neoadjuvant use in HER2-positive breast cancer.

Less than half of adolescents and young adults who survive Hodgkin lymphoma receive recommended services within the first year after treatment.

Combination of sialidase and cucurbitacin I shows substantial antitumor activity in sarcoma therapy.

The combined impact of anti-cancer treatments and exercise holds promise for shrinking tumors.

Recent advances and updates in oncology and cancer drug development.

Catch up with the latest developments across the health care landscape and sign up for key upcoming conferences.

Everolimus (Afinitor) treats progressive, non-functional neuroendocrine tumors of gastrointestinal or lung origin.

Everolimus (Afinitor) treats progressive, non-functional neuroendocrine tumors of gastrointestinal or lung origin.

Gazyva plus bendamustine provides a new option to significantly reduce the risk of death.

The management of individual chemotherapy regimens by pharmacists improves safety by reducing medication errors.

FDA approval for Gazyva gives new option to patients with follicular lymphoma who did not respond to a regimen containing rituximab (Rituxan).

Early lineage T cells show promise in the treatment of acute lymphoblastic leukemia.

Interferon therapy not recommended for patients with minimal cancer in one lymph node.

Jury orders Johnson & Johnson to pay $72 million in damages to the family of a woman who died from ovarian cancer allegedly caused by products containing talcum powder.